JPRN-jRCT2080221243未知2 期
A Phase II/III Study to Assess the Safety and Immunogenicity of subcutaneous DNK-FLU in Healthy Japanese Children
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 至 <= 12age old（—）
- 性别
- All
入选标准
- •Healthy Child
排除标准
- •Known history of influenza or received influenza vaccination within six months.
研究者
相似试验
未知
2 期
DNK-ADUFLU-3JPRN-jRCT2080222415DENKA SEIKEN CO.,LTD.50
进行中（未招募）
1 期
A PHASE II STUDY OF THE EFFICACY, SAFETY AND IMMUNOGENICITY OF ONCOVEX GM CSF IN PATIENTS WITH STAGE IIIc AND STAGE IV MALIGNANT MELANOMAStage IIIc and stage IV malignant melanomaEUCTR2006-003841-17-GBBioVex Inc60
进行中（未招募）
1 期
Study to determine the safety and immunogenicity of COVID-eVax, a vaccine for COVID-19 in healthy adult volunteers.COVID-19 prevention.MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-003734-20-ITTakis S.r.l.160
进行中（未招募）
1 期
A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio)therapy, to patients with MAGE-A3-positive Non-Small Cell Lung cancer (stage IB, II or III) - MAGE3-AS15-NSC-001on-Small Cell Lung CancerMedDRA version: 6.1Level: PTClassification code 10061873EUCTR2006-004777-10-ITGlaxoSmithKline Biologicals70
进行中（未招募）
1 期
A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without standard adjuvant chemo(-radio)therapy, to patients with MAGE A3-positive Non-Small Cell Lung Cancer (stage IB, II or III) - MAGE3-AS15-NSC-001 (ADJ-Chemo)EUCTR2006-004777-10-GBGlaxoSmithKline Biologicals72